​For dates of service on or after July 11, 2022, AmeriHealth will update Medical Policy #07.07.09i: Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic Conditions for members enrolled in AmeriHealth plans.

Autologous platelet-rich plasma (PRP) for the treatment of all orthopedic conditions is considered experimental/investigational effective July 11, 2022.

For detailed changes, please refer to the Policy Notification, which was posted on April 11, 2022.